Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
Favorskaya, I. A.; Shcheblyakov, D. V.; Esmagambetov, I. B.; Dolzhikova, I. V.; Alekseeva, I. A.; Korobkova, A. I.; Voronina, D. V.; Ryabova, E. I.; Derkaev, A. A.; Kovyrshina, A. V.; Iliukhina, A. A.; Botikov, A. G.; Voronina, O. L.; Egorova, D. A.; Zubkova, O. V.; Ryzhova, N. N.; Aksenova, E. I.; Kunda, M. S.; Logunov, D. Y.; Naroditsky, B. S.; Gintsburg, A. L.
Show abstract
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody 98%
- SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications 97%
- Immunodominant and neutralizing linear B cell epitopes spanning the spike and membrane proteins of Porcine Epidemic Diarrhea Virus 94%
Similar papers in this journal
- Increased receptor affinity and reduced recognition by specific antibodies contribute to immune escape of SARS-CoV-2 variant Omicron 95%
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 95%
- Preclinical establishment of a divalent vaccine against SARS-CoV-2 94%
Similar papers in this journal
- Selection of Human Single Domain Antibodies (sdAb) Against Thymidine Kinase 1 and Their Incorporation Into sdAb-Fc Antibody Constructs For Potential Use In Cancer Therapy 96%
- Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 95%
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 95%
Similar papers in this journal
- ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection 95%
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity 95%
- In silico, in vitro and in cellulo models for monitoring SARS-CoV-2 spike/human ACE2 complex, viral entry and cell fusion 94%
Similar papers in this journal
- A Novel High-Throughput Single B-Cell Cloning Platform for Isolation and Characterization of High-Affinity and potent SARS-CoV-2 Neutralizing Antibodies 96%
- Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro 96%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.